Clot Waveform Analysis for Hemostatic Abnormalities

키워드

참고문헌 (43)

1. Wada H, "Update on the clot waveform analysis", Clin Appl Thromb Hemost, 26, pp.1076029620912027~ (2020)
2. Sevenet PO, "Clot waveform analysis : where do we stand in 2017?", Int J Lab Hematol, 39, pp.561~568 (2017)
3. Nogami K, "Clot waveform analysis for monitoring hemostasis", Semin Thromb Hemost (2022)[DOI]
4. Arai S, "Screening method for congenital dysfibrinogenemia using clot waveform analysis with the Clauss method", Int J Lab Hematol, 43, pp.281~289 (2021)
5. Wada H, "The reevaluation of thrombin time using a clot waveform analysis", J Clin Med, 10, pp.4840~ (2021)
6. Wu Y, "Thrombin generation assay : the present and the future", Blood Coagul Fibrinolysis, 34, pp.1~7 (2023)
7. Thakkar M, "Thromboelastography in microsurgical reconstruction : a systematic review", JPRAS Open, 32, pp.24~33 (2022)
8. Shima M, "Understanding the hemostatic effects of recombinant factor VIIa by clot wave form analysis", Semin Hematol, 41(Suppl 1), pp.125~131 (2004)
9. Matsumoto T, "A combined approach using global coagulation assays quickly differentiates coagulation disorders with prolonged aPTT and low levels of FVIII activity", Int J Hematol, 105, pp.174~183 (2017)
10. Toh CH, "Waveform analysis of clotting test optical profiles in the diagnosis and management of disseminated intravascular coagulation(DIC)", Clin Lab Haematol, 24, pp.321~327 (2002)
11. Tokutake T, "Exogenous magnesium chloride reduces the activated partial thromboplastin times of lupus anticoagulant-positive patients", PLOS ONE, 11, pp.e0157835~ (2016)
12. Matsumoto T, "Frequency of abnormal biphasic aPTT clot waveforms in patients with underlying disorders associated with disseminated intravascular coagulation", Clin Appl Thromb Hemost, 12, pp.185~192 (2006)
13. Toh CH, "Biphasic transmittance waveform in the APTT coagulation assay is due to the formation of a Ca(++)-dependent complex of C-reactive protein with very-low-density lipoprotein and is a novel marker of impending disseminated intravascular coagulation", Blood, 100, pp.2522~2529 (2002)
14. Shima M, "The utility of activated partial thromboplastin time(aPTT)clot waveform analysis in the investigation of hemophilia A patients with very low levels of factor VIII activity(FVIII : C)", Thromb Haemost, 87, pp.436~441 (2002)
15. Maeda K, "Evaluation of hemostatic abnormalities in patients who underwent major hepatobiliary pancreatic surgery using activated partial thromboplastin time-clot waveform analysis", Thromb Res, 201, pp.154~160 (2021)
16. Winter WE, "Clotting factors : clinical biochemistry and their roles as plasma enzymes", Adv Clin Chem, 94, pp.31~84 (2020)
17. Al-Amer OM, "The role of thrombin in haemostasis", Blood Coagul Fibrinolysis, 33, pp.145~148 (2022)
18. Monroe DM, "Platelets and thrombin generation", Arterioscler Thromb Vasc Biol, 22, pp.1381~1389 (2002)
19. Konstantinidi A, "Clinical application of thromboelastography", thromboelastometry(TEG, Semin Thromb Hemost, pp.2019, 45[DOI]
20. Matsumoto T, "An evaluation of the activated partial thromboplastin time waveform", Clin Appl Thromb Hemost, 24, pp.764~770 (2018)
21. Katayama H, "An evaluation of hemostatic abnormalities in patients with hemophilia according to the activated partial thromboplastin time waveform", Clin Appl Thromb Hemost, 24, pp.1170~1176 (2018)
22. Wada H, "Effects of platelet and phospholipids on clot formation activated by a small amount of tissue factor", Thromb Res, 193, pp.146~153 (2020)
23. Hasegawa M, "The evaluation of hemostatic abnormalities using a CWA-small amount tissue factor induced FIX activation assay in major orthopedic surgery patients", Clin Appl Thromb Hemost, 27, pp.10760296211012094~ (2021)
24. Fan BE, "COVID-19 associated coagulopathy in critically ill patients : a hypercoagulable state demonstrated by parameters of haemostasis and clot waveform analysis", J Thromb Thrombolysis, 51, pp.663~674 (2021)
25. Tripodi A, "Thrombin generation assay and its application in the clinical laboratory", Clin Chem, 62, pp.699~707 (2016)
26. Bendetowicz AV, "The effect of subcutaneous injection of unfractionated and low molecular weight heparin on thrombin generation in platelet rich plasma—a study in human volunteers", Thromb Haemost, 72, pp.705~712 (1994)
27. Wakui M, "Distinct features of bivalent direct thrombin inhibitors, hirudin and bivalirudin, revealed by clot waveform analysis and enzyme kinetics in coagulation assays", J Clin Pathol, 72, pp.817~824 (2019)
28. Wakui M, "Assessment of in vitro effects of direct thrombin inhibitors and activated factor X inhibitors through clot waveform analysis", J Clin Pathol, 72, pp.244~250 (2019)
29. Wada H, "The evaluation of APTT reagents in reference plasma, recombinant FVIII products; Kovaltry® and Jivi® using CWA, including sTF", 7FIX assay, 2021, pp.27, 1076029620976913~
30. Bourguignon A, "Update on platelet procoagulant mechanisms in health and in bleeding disorders", Int J Lab Hematol, 44(Suppl 1), pp.89~100 (2022)
31. Wada H, "Clot waveform analysis demonstrates low blood coagulation ability in patients with idiopathic thrombocytopenic purpura", J Clin Med, 10, pp.5987~ (2021)
32. Nogami K, "Modified clot waveform analysis to measure plasma coagulation potential in the presence of the anti-factor IXa", factor X bispecific antibody emicizumab, 2018, pp.16, 1078~1088
33. Ogiwara K, "Anti-idiotype monoclonal antibodies against emicizumab enable accurate procoagulant and anticoagulant assays, irrespective of the test base, in the presence of emicizumab", Haemophilia, 29, pp.329~335 (2023)
34. Kumano O, "Evaluation of newly-developed modified diluted prothrombin time reagent in non-valvular atrial fibrillation patients with direct oral anticoagulants : a comparative study with conventional reagents", Int J Lab Hematol, 45, pp.119~125 (2023)
35. Wada H, "Routine measurements of factor VIII activity and inhibitor titer in the presence of emicizumab utilizing anti-idiotype monoclonal antibodies : comment", J Thromb Haemost, 17, pp.555~556 (2019)
36. Onishi T, "The balance of comprehensive coagulation and fibrinolytic potential is disrupted in patients with moderate to severe COVID-19", Int J Hematol, 115, pp.826~837 (2022)
37. Nogami K, "A novel simultaneous clot-fibrinolysis waveform analysis for assessing fibrin formation and clot lysis in haemorrhagic disorders", Br J Haematol, 187, pp.518~529 (2019)
38. Kobayashi M, "A clot waveform analysis showing a hypercoagulable state in patients with malignant neoplasms", J Clin Med, 10, pp.5352~ (2021)
39. Menegatti M, "Clinical and laboratory diagnosis of rare coagulation disorders(RCDs)", Thromb Res, 196, pp.603~608 (2020)
40. Lowe A, "Effects of emicizumab on APTT, FVIII assays and FVIII inhibitor assays using different reagents: results of a UK NEQAS proficiency testing exercise", Haemophilia, 26, pp.1087~1091 (2020)
41. Wada H, "A clot waveform analysis of thrombin time using a small amount of thrombin is useful for evaluating the clotting activity of plasma independent of the presence of emicizumab", J Clin Med, 11, pp.6142~ (2022)
42. Onishi T, "Coagulation and fibrinolysis balance in disseminated intravascular coagulation", Pediatr Int, 63, pp.1311~1318 (2021)
43. Kamon T, "The detection of hypercoagulability in patients with acute cerebral infarction using a clot waveform analysis", Clin Appl Thromb Hemost, 29, pp.10760296231161591~ (2023)

관련 논문AI추천